Therapy Areas: Cardiovascular
Cerenis Therapeutics acquires LYPRO Biosciences
8 November 2017 -

France-based biopharmaceutical company CERENIS Therapeutics (EPA: CEREN) has acquired LYPRO Biosciences, a therapeutic development firm specialising in proprietary drug delivery nanotechnology, the company confirmed on Wednesday.

LYPRO Biosciences leverages drug delivery nanotechnologies to increase the solubility and bioavailability of hydrophobic drugs and other therapeutic compounds and facilitate targeting to specific receptors.

Cerenis, a multinational that works primarily in the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, said that the move will solidify its position at the forefront of the chemotherapy drug delivery and immuno-oncology space.

Jean-Louis Dasseux, CEO of CERENIS Therapeutics, commented: "Building on the strong foundation of our lead HDL product, CER-001, this acquisition opens another therapeutic area characterised by a significant unmet medical need, while allowing us to leverage our leading HDL therapy capabilities to drive the development of this potentially revolutionary technology.

"We look forward to initiating the Phase I trial of NanoDisk and advancing other HDL-based assets, including CER-209 for NAFLD and NASH, in order to create value for patients, the medical community and other key stakeholders of CERENIS Therapeutics. Our enthusiasm about the fully enrolled TANGO trial continues, with results expected at the end of Q1, 2018."

Login
Username:

Password: